3Bederson J B, Connolly E S, Jr Batjer H H, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association [J]. Stroke, 2009, 40(3): 994-1025.
4Juvela S. Plasm aendothelin concentrations after aneurismal subarachnoid hemorrhage [J]. J Neurosurg, 2000, 92(3): 390-400.
6Uwe K. A Process for the preparation of 2-carbamo- yl-pyridines [P]. Europe: 0979822, 2000-02-16.
7Roux S, Breu V, Giller T, et al. Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm [J]. J Pharmacol Exp Ther, 1997, 283(3): 1110-1118.
8Macdonald R L. Clazosentan: an endothelin receptor antagonist for treatment of vasospasm atter subarachnoid hemorrhage [J]. Expert Opin Investig Drugs, 2008, 17 (11): 1761-1767.
9Macdonald R L, Kassell N F, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONS- CIOUS-1): randomized, doubleblind, placebo-controlled phase 2 dose-finding trial [J]. Stroke, 2008, 39(11): 3015-3021.
10Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage results of a randomized, double-blind, placebo-controlled, mulficenter phase IIa study [J]. JNeurosurg, 2005, 103(7): 9-17.
